CDEX Expands Management Team With Addition of Chief Financial Officer

TUCSON, AZ, Jan 22 (MARKET WIRE) --
CDEX Inc. (OTCBB: CEXI) announces that August F. DeLuca has been appointed
Chief Financial Officer and Vice President of Finance. Mr. DeLuca has been
CDEX's acting CFO for the past nine months. In his new role, Mr. DeLuca will
supervise all accounting and financial activities, treasury, financial modeling
and
risk management. Mr. DeLuca has a distinguished career of over 30 years of
service in senior level financial positions. He has served as CFO of a number
of companies, both public and private (Mr. DeLuca's bio is on the CDEX web
site at www.cdex-inc.com).

"CDEX is a cutting edge, technology/product development company that fits
well
with my technical, financial and management background," said Mr. Deluca.
"The products that we are bringing to the marketplace are addressing major
problems which makes the job both interesting and internally rewarding. I
look forward to helping CDEX achieve its potential in the national and
international arenas."

"Augie has been an invaluable part of the CDEX Team over the past nine
months,
as he has guided our financial activities," said Malcolm Philips, CDEX CEO. "We
are pleased that he has decided to join the Team on a more formal basis and
become our CFO and VP of Finance, as well. With his financial leadership and
the recent addition of financial expertise on our Board, we will be able to
chart a more effective financial course as we expand and diversify our
revenue base into other commercial markets."

CDEX is a technology company that currently has two product lines in
different commercial markets. The CDEX ID2 ("Meth Scanner(TM)") is a hand
held, battery operated scanner that detects low nanogram range quantities of
methamphetamine from standoff distances of 2-8 inches without disturbing the
surfaces under investigation. Meth Scanner technology is used in the CDEX
ValiMed(TM) Medication Validation System currently deployed in major hospitals
across the United States. (See www.cdex-inc.com or www.valimed.com)

About CDEX Inc.

CDEX, a technology company currently developing products using its
patented/patent pending chemical detection technologies, is focused on (i)
identification of substances of concern (e.g., explosives and illegal drugs, for
security markets); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of compounded
medication and detection of counterfeit or sub-par products, for the medical and
brand protection markets). ValiMed(TM) and the Meth Scanner(TM) are CDEX
solutions for the healthcare and security markets. Corporate headquarters and
R&D
facilities are located in Tucson, Arizona. For more information, visit
www.cdex-inc.com and www.valimed.com or contact Malcolm Philips
(mphilips@cdex-inc.com)
or Stuart Poteet (spoteet@cdex-inc.com) 520.745.5172 X 210 or 201.

Any Non-Historical statements are forward-looking, as defined in federal
securities laws, and generally can be identified by words such as "expects,"
"plans," "may," "anticipates," "believes," "should," "intends," "estimates," and
other similar words. These statements pose risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied. Such risks and uncertainties
include, without limitation, the effectiveness, profitability and marketability
of
products, the Protection of intellectual property and proprietary information,
and
other risks detailed from time-to-time in filings with the Sec. There is no
obligation to publicly update any forward-looking statements.

Contact:

Malcolm Philips
mphilips@cdex-inc.com
520.745.5172 X 210

Stuart Poteet
spoteet@cdex-inc.com
520.745.5172 X 201

Copyright 2008, Market Wire, All rights reserved.

-0-